Page 14 - CIBEREHD-2016-cast

Publicaciones más relevantes del CIBEREHD durante 2016 según factor de impacto
Publicación
Factor Impacto
Bonaccorsi-Riani E., Pennycuick A., Londono M.-C., Lozano J.-J., Benitez C., Sawitzki B. et
al. Molecular Characterization of Acute Cellular Rejection Occurring during Intentional Immunosuppression Withdrawal in Liver Transplantation. American Journal of Transplantation. 2016;16(2):484-496.
5,669
Fernandez-Calotti P., Casulleras O., Antolin M., Guarner F., Pastor-Anglada M. Galectin-4 interacts with the drug transporter human concentrative nucleoside transporter 3 to regulate its function. FASEB Journal. 2016;30(2):544-554.
5,299
Morales-Ibanez O., Affo S., Rodrigo-Torres D., Blaya D., Millan C., Coll M. et al. Kinase analysis in alcoholic hepatitis identifies p90RSK as a potential mediator of liver fibrogenesis. Gut. 2016.
14,921
Manns M., Samuel D., Gane E.J., Mutimer D., McCaughan G., Buti M. et al. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. The Lancet Infectious Diseases. 2016;16(6):685-697.
21,372
Blaya D., Coll M., Rodrigo-Torres D., Vila-Casadesus M., Altamirano J., Llopis M. et al. Integrative microRNA profiling in alcoholic hepatitis reveals a role for microRNA-182 in liver injury and inflammation. Gut. 2016.
14,921
Urtasun R., Elizalde M., Azkona M., Latasa M.U., Garcia-Irigoyen O., Uriarte I. et al. Splicing regulator SLU7 preserves survival of hepatocellular carcinoma cells and other solid tumors via oncogenic miR-17-92 cluster expression. Oncogene. 2016;35(36):4719-4729.
7,932
Carballal S., Rodriguez-Alcalde D., Moreira L., Hernandez L., Rodriguez L., Rodriguez-Moranta F. et al. Colorectal cancer risk factors in patients with serrated polyposis syndrome: A large multicentre study. Gut. 2016.
14,921
Reig M., Marino Z., Perello C., Inarrairaegui M., Ribeiro A., Lens S. et al. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. Journal of Hepatology. 2016;65(4):719-726.
10,59
Gisbert J.P., Marin A.C., Chaparro M. The risk of relapse after Anti-TNF discontinuation in inflammatory bowel disease: Systematic review and meta-analysis. American Journal of Gastroenterology. 2016;111(5):632-647.
10,383
Panes J., Garcia-Olmo D., Van Assche G., Colombel J.F., Reinisch W., Baumgart D.C. et al. Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn’s disease: A phase 3 randomised, double-blind controlled trial. The Lancet. 2016.
44,002
1243